NYSE:JNJPharmaceuticals
Johnson & Johnson (JNJ) Stock Faces Margin Squeeze As Q2 Net Profitability Undercuts Bullish Narrative
Johnson & Johnson (JNJ) just posted Q2 2026 revenue of US$25.3 billion and basic EPS of US$2.27, with trailing 12 month EPS at US$8.70 and net income of US$21.0 billion framing the latest quarter against a much larger earnings base. Over recent quarters the company has seen revenue move from US$23.7 billion in Q2 2025 through a range of roughly US$24.0 billion to US$24.6 billion, while quarterly EPS has tracked between US$2.10 and US$2.30 outside of a one off spike in early 2025. This sets a...